查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1703358

風濕病治療市場－全球產業規模、佔有率、趨勢、機會和預測（按適應症、配銷通路、地區和競爭細分，2020-2030 年）

Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球風濕病治療市場價值為 261.1 億美元，預計到 2030 年將達到 370.5 億美元，預測期內年複合成長率(CAGR) 為 5.98%。

市場概覽
預測期 2026-2030
2024年市場規模 261.1億美元
2030年市場規模 370.5億美元
2025-2030 年複合年成長率 5.98%
成長最快的領域 網路藥局
最大的市場 北美洲

風濕病治療學是醫學科學的一個專門領域，專注於風濕病的診斷和治療，風濕病主要影響肌肉骨骼系統 - 關節、肌肉、骨骼和結締組織。這些情況通常表現為關節疼痛、僵硬、發炎和活動受限。治療方法旨在緩解症狀、控制病情進展並提高患者的生活品質。

類風濕性關節炎、骨關節炎和狼瘡等疾病的發生率和盛行率不斷上升，推動了對風濕病治療的需求。主要促成因素包括全球人口老化和生活方式的改變。生物療法（如 TNF 抑制劑、白血球介素抑制劑和 JAK 抑制劑）繼續佔據市場主導地位，這得益於持續的研發推出更有效的治療方案。

關鍵市場促進因素

風濕病患病率上升

主要市場挑戰

治療費用高昂

儘管生物相似藥有望降低治療成本，但由於市場猶豫以及醫療保健提供者和患者的認知有限，更廣泛的採用仍然是一個障礙。

主要市場趨勢

轉向以病人為中心的護理

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球風濕病治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依適應症（僵直性脊椎炎、痛風、骨關節炎、乾癬關節炎、類風濕性關節炎）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：亞太風濕病治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第7章：歐洲風濕病治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 8 章：北美風濕病治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第9章：南美洲風濕病治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲風濕病治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章：全球風濕病治療市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Amgen Inc.
  • Novartis AG
  • Janssen Pharmaceuticals, Inc.
  • Sanofi SA
  • Johnson & Johnson Private Limited
  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 16870

Global Rheumatology therapeutics market was valued at USD 26.11 billion in 2024 and is projected to reach USD 37.05 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.98% during the forecast period.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 26.11 Billion
Market Size 2030USD 37.05 Billion
CAGR 2025-20305.98%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Rheumatology therapeutics is a specialized area of medical science focused on the diagnosis and treatment of rheumatic diseases, which primarily affect the musculoskeletal system-joints, muscles, bones, and connective tissues. These conditions commonly manifest as joint pain, stiffness, inflammation, and limited mobility. The therapeutic approach aims to alleviate symptoms, manage disease progression, and enhance the quality of life for patients.

The increasing incidence and prevalence of conditions such as rheumatoid arthritis, osteoarthritis, and lupus are fueling demand for rheumatology therapeutics. Key contributing factors include an aging global population and lifestyle-related changes. Biologic therapies-such as TNF inhibitors, interleukin inhibitors, and JAK inhibitors-continue to dominate the market, driven by ongoing R&D introducing more effective treatment options.

Key Market Drivers

Rising Prevalence of Rheumatic Diseases

The growing global burden of rheumatic conditions-including osteoarthritis, rheumatoid arthritis, and gout-can be attributed to several interrelated factors. Aging demographics are a major contributor, with conditions like osteoarthritis increasing proportionally with age. In 2019, approximately 528 million people globally were affected by osteoarthritis, representing a 113% rise since 1990. Nearly 73% of these individuals were over the age of 55.

Obesity is another key risk factor. In 2022, one in eight people globally were classified as obese, with adult obesity rates more than doubling since 1990. Additionally, sedentary lifestyles-prevalent in modern societies-have been linked to a surge in musculoskeletal and joint disorders. As of 2022, nearly one-third of adults worldwide were insufficiently physically active.

Genetic predisposition also plays a significant role. For example, heritability in rheumatoid arthritis is estimated at around 60%, with strong associations to specific genetic markers such as HLA. Environmental factors like air pollution have also been linked to the development and exacerbation of these conditions.

Improvements in diagnostic tools and heightened awareness among healthcare professionals have led to earlier and more accurate diagnoses. In the U.S., 21.2% of adults-approximately 53.2 million people-were diagnosed with arthritis between 2019 and 2021. Many of these diseases are chronic, further increasing prevalence due to long-term disease management.

Gender disparities are also notable; rheumatoid arthritis affects women two to three times more frequently than men. Additionally, rheumatic conditions often coexist with comorbidities such as cardiovascular disease and diabetes, compounding the healthcare burden. Regional differences in diet, healthcare access, and lifestyle also influence prevalence rates. Collectively, these factors underscore the growing need for effective rheumatology therapeutics and continued innovation in treatment approaches.

Key Market Challenges

High Cost of Treatment

One of the primary challenges in the rheumatology therapeutics market is the high cost of treatment, particularly for biologic drugs. Despite insurance coverage, patients frequently incur substantial out-of-pocket expenses, leading to treatment non-adherence and poorer health outcomes.

These high costs can exacerbate disparities in care access, particularly among lower-income populations, resulting in delayed diagnoses and suboptimal treatment. Publicly funded healthcare systems also face budgetary constraints that limit the availability and quality of rheumatologic treatments.

Moreover, the cost burden extends to health insurers and employers, often resulting in increased insurance premiums. Concerns over affordability have prompted discussions among policymakers and advocacy groups regarding drug pricing reforms and greater transparency in healthcare costs.

Rheumatic diseases can significantly impair physical functioning, resulting in decreased work productivity and higher disability rates. The combined effect of disease burden and high treatment costs poses economic challenges for individuals and healthcare systems alike.

Although biosimilars hold promise for reducing treatment costs, broader adoption remains a hurdle due to market hesitancy and limited awareness among healthcare providers and patients.

Key Market Trends

Shift Toward Patient-Centric Care

The market is witnessing a paradigm shift toward patient-centered care, with a strong emphasis on shared decision-making. Healthcare providers are involving patients in the development of personalized treatment plans, taking into account disease severity, lifestyle, comorbidities, and individual preferences.

Education and empowerment are integral components of this approach. By equipping patients with a better understanding of their condition and available treatment options, providers can foster more active patient participation in disease management.

Efforts are also being made to address access and affordability challenges. Healthcare institutions are working to minimize financial barriers and ensure equitable access to necessary treatments.

Patient-centric models promote continuous monitoring of disease activity, encouraging patients to communicate regularly with their healthcare teams. Pain management, as a core concern, is customized based on individual needs.

Key Market Players

  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Amgen Inc.
  • Novartis AG
  • Janssen Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson Private Limited
  • F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Rheumatology Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rheumatology Therapeutics Market, By Indication:

  • Ankylosing Spondylitis
  • Gout
  • Osteoarthritis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis

Rheumatology Therapeutics Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Rheumatology Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rheumatology Therapeutics Market.

Available Customizations:

Global Rheumatology Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rheumatology Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Ankylosing Spondylitis, Gout, Osteoarthritis, Psoriatic Arthritis, Rheumatoid Arthritis)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Rheumatology Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Rheumatology Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. India Rheumatology Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Australia Rheumatology Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Distribution Channel
    • 6.3.4. Japan Rheumatology Therapeutics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Indication
        • 6.3.4.2.2. By Distribution Channel
    • 6.3.5. South Korea Rheumatology Therapeutics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Indication
        • 6.3.5.2.2. By Distribution Channel

7. Europe Rheumatology Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Rheumatology Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. Germany Rheumatology Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. Spain Rheumatology Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Rheumatology Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. United Kingdom Rheumatology Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Distribution Channel

8. North America Rheumatology Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Rheumatology Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. Mexico Rheumatology Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Canada Rheumatology Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Distribution Channel

9. South America Rheumatology Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Rheumatology Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. Argentina Rheumatology Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. Colombia Rheumatology Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Rheumatology Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Rheumatology Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Saudi Arabia Rheumatology Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. UAE Rheumatology Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Rheumatology Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. AbbVie Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Bristol-Myers Squibb Company
  • 16.3. Pfizer Inc.
  • 16.4. Merck & Co., Inc.
  • 16.5. Amgen Inc.
  • 16.6. Novartis AG
  • 16.7. Janssen Pharmaceuticals, Inc.
  • 16.8. Sanofi SA
  • 16.9. Johnson & Johnson Private Limited
  • 16.10. Takeda Pharmaceutical Company Limited
  • 16.11. F. Hoffmann-La Roche Ltd

17. Strategic Recommendations

18. About Us & Disclaimer